Etanercept in psoriatic arthritis

Expert Opinion on Biological Therapy

Volumn 3, Issue 1, 2003, Pages 169-177

  Anandarajah, Allen P ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Disease modifying antirheumatic drug; Etanercept; Psoriatic arthritis; TNF ; Treatment

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANALGESIC AGENT; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; EFALIZUMAB; ETANERCEPT; HORMONE; INFLIXIMAB; LEFLUNOMIDE; LIVE VACCINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ONERCEPT; PNEUMOCOCCUS VACCINE; PREDNISONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR BINDING PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANEMIA; ANTIINFLAMMATORY ACTIVITY; APLASTIC ANEMIA; ARTHRALGIA; AUTOIMMUNE DISEASE; BACTERIAL ARTHRITIS; BLOOD TOXICITY; CANCER; CELLULITIS; CLINICAL TRIAL; COUGHING; DEMYELINATING DISEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPEPSIA; EDEMA; ERYTHROCYTE SEDIMENTATION RATE; HEADACHE; HUMAN; INFECTION; INFLAMMATION; INJECTION; LEUKOPENIA; MOUTH ULCER; MYELITIS; NAUSEA; NEUROTOXICITY; OPPORTUNISTIC INFECTION; OPTIC NERVE DISEASE; OSTEOMYELITIS; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PSORIATIC ARTHRITIS; PYELONEPHRITIS; QUALITY OF LIFE; RADIOGRAPHY; RASH; REVIEW; RHEUMATOID ARTHRITIS; RHINITIS; SEIZURE; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

ANIMALS; ARTHRITIS, PSORIATIC; CLINICAL TRIALS; DRUG EVALUATION; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS;

BACTERIA (MICROORGANISMS); QUERCUS;

EID: 0037322567     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.3.1.169     Document Type: Review

References (57)

1. GABRIEL SE: The epidemiology of psoriatic arthritis. J. Rheumatol. (2001) 28(3):678.
2. GLADMAN DD: Psoriatic arthritis. Rheum. Dis. Clin. (1998) 24:829-844. Excellent comprehensive review.
3. WINCHESTER R: Psoriatic Arthritis. In: Dermatology in General Medicine, Fitzpatrick FM, Austin K (Eds), New York, McGraw-Hill, (1993):515-527.
4. GLADMAN DD, FAREWELL VT, WONG K, HUSTED J: Mortality studies in psoriatic arthritis: results from a single outpatients center - II: prognostic indicators for death. Arthritis Rheum. (1998) 41:1103-1110.
5. BRUCE I, GLADMAN DD: Psoriatic arthritis. Recognition and management. Biodrugs (1998) 9:27-36.
6. PALIT J, HILL J, CAPELL HA et al: A multicenter double-blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br. J. Rheumatol. (1990) 29:280-283.
7. FARR M, KITAS GD, WATERHOUSE L, JUBB R, FELIX-DAVIES D, BACON PA: Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study. Br. J. Rheum. (1990) 29:46-49.
8. ELLIS CN, FRADIN MS, MESSANA JM et al.: Cyclosporine for plaque-type psoriasis. N. Engl. J. Med. (1991) 324:277-284.
9. LE QUINTREC JL, MENKES CJ, AMOR B: Severe psoriatic rheumatism. Treatment with azathioprine. Report of 11 cases. Rev. Rheum. Mal. Osteoartic. (1990) 57:815-819.
10. SAYERS ME, MAZANEC DJ: Use of antimalarial drugs for the treatment of psoriatic arthritis. Am. J. Med. (1992) 93:474-475.
11. BLACK RL, O'BRIEN WM, VAN SCOTT EJ, AUERBACH R, EISEN AZ, BUNIM JJ: Methotrexate therapy in psoriatic arthritis. JAMA (1964) 189:141-145.
12. ESPINOZA LR, ZAKRAOUI L, ESPINOZA CG et al: Psoriatic arthritis: clinical response and side effects of methotrexate therapy. J. Rheumatol. (1992) 19:872-877.
13. WILKENS RF, WILLIAMS HJ, WARD JR et al.: Randomized, double-blind, placebo controlled trial of low dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. (1984) 27:376-381. Controlled trial of methotrexate in PsA.
14. ABU-SHAKRA M, GLADMAN DD, THORNE JC, LONG J, GOUGH J, FAREWELL VT: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J. Rheumatol. (1995) 22:241-245.
15. MEASE PJ: Tumor necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann. Rheum. Dis. (2002) 61:298-304.
16. VILCEK J, LEE TH: Tumor necrosis factor: a new insight into the molecular mechanisms of its multiple actions. J. Biol. Chem. (1991) 266:7313-7316.
17. BAZZONI F, BUETLER B: The tumor necrosis factor ligand and receptor families. N. Engl. J. Med. (1996) 26:1717-1725. Comprehensive but somewhat dated review of the TNF family.
18. BRENNAN FM, FELDMAN M: Cytokines in autoimmunity. Curr. Opin. Immunol. (1992) 4:754-759.
19. SAXNE T, PALLADINO MA JR, HEINNGARD D et al.: Detection of tumor necrosis factor-alpha but not tumor necrosis factor-beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. (1988) 31:1041-1045.
20. SMITH CA, DAVIS T, ANDERSON D et al.: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science (1990) 248:1019-1023.
21. MOHLER KM, TORRANCE DS, SMITH CA et al.: Soluble rumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and simultaneously as both TNF carriers and TNF antagonists. J. Immunol. (1993) 151:1548-1561.
22. KEFFER J, PROBERT L, CAZLARIS H et al.: Transgenic mice expressing human tumor necrosis factor: a predictive genetic model of arthritis. EMBO J. (1991) 10:4025-4031.
23. RITCHLIN C, HAAS-SMITH SA, HICKS D, CAPPUCIO J, OSTERLAND CK, LOONEY RJ: Patterns of cytokine production in psoriatic synovium. J. Rheumatol. (1998) 25:1544-1552.
24. DANNING CL, ILLEI GG, HITCHON C, GREER MR, BOUMPAS DT, MCINNES IB: Macrophage-derived cytokine and nuclear factor κB p65 expression in synovial membrane and skin of patients with PsA. Arthritis Rheum. (2000) 43:1244-1256.
25. BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Immunomodulatory effects of anti-tumor necrosis factor (alpha) therapy on synovium in spondyloarthropathy: histologic findings in 8 patients from an open label pilot study. Arthritis Rheum. (2001) 44:186-195.
26. MORELAND LW, SCHIFF, BAUMGARTEN SW et al.: Etanercept therapy in rheumatoid arthritis. Ann. Intern. Med. (1990) 130:478-486.
27. WEINBLATT MF, KREMER JM, BANKHURST AD et al.: A trial of recombinant tumor necrosis factor receptor-Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
28. LOVELL DJ, GIANNINI EH, REIFF A et al.: Etanercept in children with polyarticular juvenile rheumatoid arthritis. N. Engl. J. Med. (2000) 342(11):763-769.
29. BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
30. WYETH: Summary of product characteristics: Enbrel™ (January 2002).
31. ALLDRED A: Etnercept in rheumatoid arthritis. Expert Opin. Pharmacother. (2001) 2(7):1137-1148. Detailed review of etanercept from a pharmacologic perspective.
32. MEASE P, RITCHLIN C, MARTIN R, BAUMGARTNER S, BURGE D: Response to pneumococcal vaccination in patients treated with etanercept (Enbrel) trial. Arthritis Rheum. 44(Suppl. 231):S91.
33. MEASE PJ, GOFFE BS, METZ J, VANDERSTOEP A, FINCK B, BURGE DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet (2000) 356:385-390. Phase II trial of etanercept in PsA.
34. CLEGG DO, REDA DJ, MEJIAS E et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis: a Dept of Veterans Affairs Cooperative study. Arthritis Rheum (1996) 39:2013-2020.
35. FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
36. FREDRICKSSON T, PETERSSON U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica (1978) 157:238-244.
37. MEASE PJ, KIVITZ A, BURCH F et al.: Improvement in disease activity in patients with psoriatic arthritis receiving etanercept. Results of a phase 3 multicenter trial. Arthritis Rheum. (2001) 44(Suppl.):S90. Abstract describing results of the Phase III PsA trial.
38. ORY P, SHARP JT, SALONEN D et al.: Etanercept (ENBREL) inhibits radiographic progression in patients with psoriatic arthritis. Arthritis Rheum. (2002) 46(Suppl. 442):S196.
39. YAZICI Y, ERKAN D, LOCKSHIN MD: A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. Clin. Exp. Rheumatol. (2000) 18:732-734.
40. MARZO-ORTEGA H, MCGONAGLE D, O'CONNOR P, EMERY P: Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. A clinical and magnetic resonance imaging study. Arthritis Rheum. (2001) 44:2112-2117. Interesting study documenting suppression of enthesitis in spondyloarthropathy patients using clinical and MRI measures.
41. ZELTSER R, VALLE T, TANCK C, HOLYST MM, RITCHLIN C, GASPARI A: Clinical, histologic and immunophenotypic characteristics of injection site reactions associated with etanercept - a recombinant tumor necrosis factor-α receptor: Fc fusion protein. Dermatology (2001) 137(7):893-899.
42. WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J. Rheumatol. (2002) 29(S):33-38.
43. BRAUN J, SEIPER J: Psoriatic arthritis: role and effect of novel biologic therapies. Biodrugs (2002) (in press).
44. ROBINSON WH, GENOVESE MC, MORELAND LW: Demyelinating and neurologic events reported in association with tumor necrosis factor-(alpha) by what mechanisms could rumor necrosis factor antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum (2001) 44:1977-1983.
45. ANTONI C, KAVANAUGH A, KIRKHAM B et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum (2002) 46(Suppl. 985):S381.
46. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS E: Effects of a loading dose of three infusions of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann. Rheum. Dis. (2000) 59:428-433.
47. OGILVIE AIJ, ANTONI C, DECHANT C et al.: Treatment of psoriatic arthritis with antitumor necrosis factor-α antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br. J. Derm. (2001) 144:587-589.
48. BAETEN D, KRUITHOF E, VAN DEN BOSCH F et al.: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum. (2001) 44:186-195.
49. VAN DEN BOSCH F, KRUITHOF E, BAETEN D, DE KEYSER F, MIELANTS H, VEYS E: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum. (2002) 46:755-765.
50. ELLIS CN, KRUEGER GG: Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N. Engl. J. Med. (2001) 345(4):248-255.
51. DINANT HJ, VAN KUIJK AWR, GOEDKOOP AY et al.: Alefacept (LFA 3-IgG1 fusion protein LFA 3TIP) reduces synovial inflammatory infiltrate and improves outcome in psoriatic arthritis. Arthritis Rheum. (2001) 42(Suppl.):S91.
52. KRAAN MC, VAN KUIJK AWR, DINANT HJ et al.: Alefacept treatment in psoriatic arthritis. Arthritis Rheum. (2002) 46(10):2776-2784.
53. JONES G, CROTTY M, BROOKS P: Psoriatic arthritis: a quantitative overview of therapeutic options. Br. J. Rheum. (1997) 36:95-99.
54. HASSAN W: Methotrexate and liver toxicity: role of surveillance. Ann Dis. (1996) 53(5):273-275.
55. GRISNER LF, GILL SA, HARR MD: Liver biopsy in psoriatic arthritis methotrexate toxicity. J. Clin. Rheum. 7:224-227.
56. GORMAN JD, SACK KE, DAVIS JC JR: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor (alpha). N. Engl. J. Med. (2002) 346:1349-1356. Phase II trial demonstrating efficacy of etanercept in ankylosing spondylitis.
57. BLIDDAL H, OVISTGAARD E, TERSLEV L et al.: Injection of etanercept into arthritic joints. II: dose-response and efficacy. Ann. Rheum. Dis. (in press).